Breaking News
March 24, 2018 - Morning Break: Skip the Finger Exam? Self C-Section; Toxic Toenail Fungus
March 24, 2018 - 3-D simulations reveal synergistic mechanisms of the human heart
March 24, 2018 - Newly designed three-part molecule shows promise to treat breast cancers
March 24, 2018 - Pubertal hormones not responsible for changes in social behavior during adolescence
March 24, 2018 - Waning Vaccine Protection May Be Driving Rise in U.S. Mumps Cases
March 24, 2018 - Folic Acid in Utero Tied to Food Allergy Risk
March 24, 2018 - Trial shows safety of drugs for irregular heartbeat patients undergoing treatment
March 24, 2018 - Penn State psychologists shed light on false memories in older adults
March 24, 2018 - Patients who self-discharge should be viewed more positively, say researchers
March 24, 2018 - Wearable brain scanner enables brain imaging whilst moving
March 24, 2018 - Trump Signs $1.3 Trillion Spending Bill, Averts Shutdown
March 24, 2018 - Two drugs prevent heart problems in breast cancer patients
March 24, 2018 - Research provides better understanding of how some cancer cells resist treatment
March 24, 2018 - Certain nutrients found in food may help reduce symptoms of psychotic illness
March 24, 2018 - AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
March 24, 2018 - AHRQ Is in Trouble | Medpage Today
March 24, 2018 - Could a pap test spot more than just cervical cancer?
March 24, 2018 - Men have greater hospital readmission risk following firearm injury, study shows
March 24, 2018 - Pediatric psychologist shares 11 warning signs of childhood depression
March 24, 2018 - OncoBreak: ‘I Was Normal Once’; Ending Cervical Cancer; Mammo Controversy
March 24, 2018 - Gum Disease by the Numbers
March 24, 2018 - Studies show tool can identify individual needs, supports to help youths with autism, intellectual disabilities
March 24, 2018 - Study reveals cause of extreme nausea in pregnancy
March 24, 2018 - New findings highlight need to reconsider cervical cancer screening guidelines
March 24, 2018 - Smartwatch App Might Help Detect A-Fib
March 24, 2018 - TAVR Reasonable for Low-Flow, Low-Gradient Aortic Stenosis
March 24, 2018 - Kids with severe brain injuries may develop ADHD: study
March 24, 2018 - Researchers explore ways to help older adults taper off and stop using sedatives
March 24, 2018 - Back pain being mismanaged globally
March 24, 2018 - Fingerprint test accurately and noninvasively detects heroin, cocaine users
March 24, 2018 - Leading experts to promote cardiovascular health at EuroPrevent 2018
March 24, 2018 - A Role for Rituximab in Lupus?
March 24, 2018 - New osteoarthritis genes discovered
March 24, 2018 - Maternal intake of DHA supplement linked to higher fat-free body mass in children
March 24, 2018 - Royal College of Pathologists‘ bulletin provides summary of Tissue Handling Workshop
March 24, 2018 - Maternal alcohol use early in pregnancy may be risk factor for infant abdominal malformation
March 24, 2018 - Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection
March 24, 2018 - Accelerated WBI Should be the Norm for Most Breast Cancers
March 24, 2018 - Experts seek to standardize treatments for childhood rheumatic diseases
March 24, 2018 - Foil-based measuring chip rapidly detects Legionella
March 24, 2018 - Bariatric surgery linked to positive outcomes in very obese adolescents with type 2 diabetes
March 24, 2018 - Researchers identify chemical responsible for carcinogen formation in recycled wastewater
March 24, 2018 - Obesity and severe obesity continue to rise among U.S. adults
March 24, 2018 - Missed hospital appointments increase after spring clock change in the UK
March 24, 2018 - Researchers explore ways to manage and prevent falls in older adults with dementia
March 24, 2018 - Are there risks from secondhand marijuana smoke? Early science says yes.
March 24, 2018 - NUST MISIS researchers produce elastic metal rods for scoliosis treatment
March 24, 2018 - New University of Bath project seeks to make injections safer
March 24, 2018 - Higher-dose RT does not improve survival but reduces recurrence risk for prostate cancer patients
March 24, 2018 - Researchers examine link between knee pain and depression in older adults
March 24, 2018 - FDA Alert: BD Vacutainer Blood Collection Tubes by Becton, Dickinson and Company (BD): Class I Recall
March 24, 2018 - Daytime Sleepiness Linked to Amyloid Accumulation Without Dementia
March 24, 2018 - Energy storehouses in the brain may be source of Alzheimer’s, targets of new therapy
March 24, 2018 - Praising people with autism shows promise for producing more exercise
March 24, 2018 - Using harmless red or infrared light to diagnose breast cancer
March 24, 2018 - Clash over abortion hobbles a health bill. Again. Here’s how.
March 23, 2018 - Virtual nature environment could be new way to recover from stress
March 23, 2018 - New study identifies key cellular mechanisms behind vascular aging in mice
March 23, 2018 - Nightmares Common Among U.S. Troops, But Seldom Reported
March 23, 2018 - Another Record Low for Tuberculosis in U.S.
March 23, 2018 - Changes in the eye connected to a decline in memory
March 23, 2018 - Radiologist creates dramatic teaching tool using power of VR
March 23, 2018 - Grilled meat could be raising the risk of hypertension finds study
March 23, 2018 - Mutations found in bassoon gene may help explain cause of rare brain disorder
March 23, 2018 - Childhood Brain Injuries May be Linked to ADHD Years Later
March 23, 2018 - Why treating addiction with medication should be carefully considered
March 23, 2018 - Researchers make key discovery about cellular pathway linked to myriad of diseases
March 23, 2018 - Researchers uncover cause of rare childhood neurodegenerative disease
March 23, 2018 - Measles infection in early childhood could contribute to later COPD
March 23, 2018 - Opioid painkiller is top prescription in 11 states
March 23, 2018 - Sienna Biopharmaceuticals Announces First Patient Dosed In Proof-of-Concept Trial of Topical By Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
March 23, 2018 - In Teen Girls, Neural Patterns May Drive Emotional Resilience
March 23, 2018 - Gene-based test for urine detects, monitors bladder cancer
March 23, 2018 - BD to introduce new digital solution for IV chemotherapy administration process at EAHP 2018
March 23, 2018 - New computational method helps to identify tumor cell mutations with greater accuracy
March 23, 2018 - Researchers identify potential obesity treatment in freezing hunger-signaling nerve
March 23, 2018 - Wales participates in the 100,000 Genomes Project
March 23, 2018 - 24-Hr Paging Cuts ED Visits for Kids with Endocrine Issues
March 23, 2018 - The brain learns completely differently than we’ve assumed since the 20th century
March 23, 2018 - Less nutritious diet mainly contributes to Type 2 diabetes among U.S.-based South Asians
Genius Delayed: HIV Vaccines Still in the Works

Genius Delayed: HIV Vaccines Still in the Works

image_pdfDownload PDFimage_print

In February, mixed results were reported from a small trial with a candidate HIV vaccine, but researchers nevertheless said they were encouraged that they were on the right track. Click here to read MedPage Today’s report on that presentation. In this follow-up article, we examine what has happened since with the efforts to bring an HIV vaccine into clinical use.

In retrospect, you have to forgive Margaret Heckler’s optimism.

In 1984, Heckler — then secretary of Health And Human Services — told reporters that the cause of AIDS had been pinned down and that a blood test for the virus, then dubbed HTLV-III, had been developed.

A vaccine, she expected, would follow in the next couple of years. “Yet another terrible disease is about to yield to patience, persistence, and outright genius,” Heckler said.

What Heckler could not know, in those early years, is exactly how much patience, persistence, and genius would be needed. There is still no vaccine for HIV 33 years later and counting — but 2017 was a year of renewed optimism and clinical endeavor.

The search for a vaccine is now more nuanced. Two large randomized trials are investigating drugs that would bar the door to HIV infection in the first place — pretty much the layman’s understanding of what a vaccine does. Those trials are what HIV vaccine research has been about from the beginning — big studies with a potential for a big pay-off.

But other studies are looking at “therapeutic” vaccines, which would boost the immune systems of people already infected so they could control the virus without the need for daily antiviral medications.

On the latter front, there is now some optimism. In February, Beatriz Mothe, MD, PhD, of the Spanish AIS research institute IrsiCaixa in Barcelona, reported early details of a small study that gave, for the first time, a positive signal for a therapeutic vaccine strategy.

At the annual Conference on Retroviruses and Opportunistic Infections (CROI), Mothe reported that five people in a 15-patient trial had been able to keep the virus under control after stopping anti-HIV medications.

“They go up, they go down” but their HIV viral load remains relatively low, she told MedPage Today at the time. That’s a contrast to what usually happens when HIV patients stop taking their drugs — an almost immediate and precipitous increase in HIV.

The study has just finished, Mothe told MedPage Today recently, and the investigators are in the midst of finalizing and analyzing the data.

The viral control she reported at CROI was sustained in four patients throughout the 8-month trial and she and colleagues are now studying the virology and immunology of the participants to try to generate a hypothesis to explain the effect.

“As you can imagine, with such a small non-controlled trial, it is challenging to decipher the exact mechanisms that may explain the observed effect,” she said in an email. The researchers hope to publish their data in the next few months.

Outside experts said they were excited by the report, but cautioned it was early days. Mothe said she and colleagues are starting new trials with novel vaccine candidates that they hope will have even more of an effect.

As Mothe pointed out, the lack of a control group is a challenge for such studies. Exactly how much of a challenge was made clear later in the year.

In December, investigators from the National Institute of Allergy and Infectious Diseases (NIAID) and colleagues reported the null outcome of a placebo-controlled trial of another therapeutic vaccine strategy.

Placebo-controlled trials have been rare on the therapeutic vaccine front, largely because — by definition — participants are already infected and there is a risk associated with stopping anti-HIV drugs.

But in the NIAID trial, the researchers found it was possible to use a placebo control group safely. And they re-learned the important lesson that a control group yields valuable information about efficacy.

Many participants treated with the vaccine candidate stopped their anti-HIV medicines and did quite well for some time but so did those given a placebo. Indeed, had the trial simply compared treated patients with historical controls, the researchers might have concluded — wrongly — that they had something that worked.

The investigators pointed out that the effect they saw was very similar to what Mothe and colleagues observed.

On the preventive front, of course, placebo control is the rule. But here again, it has been a challenge to demonstrate efficacy: Only one study has shown any benefit from a vaccine candidate.

In 2009, investigators showed that a vaccine strategy tested in Thailand yielded some protection against infection — an estimated 31%. But the estimate had a wide confidence interval, from 1.1% to 52.1%, and in any case it wasn’t a strong enough result to justify using the strategy clinically.

But the approach used in that trial, dubbed RV-144, is being tested again — after some tweaks. Researchers first pored over the RV-144 data looking for clues to even that small efficacy. Then, using those clues, they re-engineered the vaccines and re-designed the way they would be used.

Late last year, a new trial, dubbed HVTN 702, kicked off in South Africa, with the goal of enrolling 5,400 people and delivering at least 50% vaccine efficacy. A spokesperson for the trial said more than 2,200 participants have already enrolled.

One reason the new trial took a long time to get under way is that the vaccines — there are actually two substances, used in a prime-boost fashion — had to be modified so they were aimed at the HIV clade that circulates in South Africa.

If it proves to be effective when results are available in 2020, variants would be needed for each HIV clade around the world.

That’s why there is some excitement about the second trial now under way — the so-called Imbokodo trial, a phase IIb proof-of-concept study, has just started enrolling 2,600 HIV-negative women in sub-Saharan Africa. The study will look at safety and efficacy.

The vaccine candidate under study is based on what are called “mosaic” immunogens — vaccine components designed to induce immune responses against a wide variety of HIV clades. In other words, if it proves to work, there would be no need to tweak the vaccine for different regions.

Results from Imbokodo (also known as HPTN 705) should be available in about 4 years.


Tagged with:

About author

Related Articles